2023-03-06 08:44:37 ET
- Bellerophon Therapeutics ( NASDAQ: BLPH ) entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct offering, 718,474 shares at $2/share and 1.78M prefunded warrants at a price of $1.99/pre-funded warrant for total gross proceeds of ~$5M.
- Net proceeds to be used for its REBUILD Phase 3 study and for working capital and general corporate purposes.
- Offer is expected to close on Mar.7, 2023.
For further details see:
Bellerophon Therapeutics to raise $5M in stock and warrants offering